ImmunityBio appoints Bruce Wendel to board of directors effective Dec. 12.

ImmunityBio, Inc.

Bruce Wendel appointed independent director effective Dec. 12, 2025; term expires at 2026 annual meeting.
Background includes Abraxis BioScience (commercialized Abraxane, led Celgene acquisition), Bristol-Myers Squibb.
Receives $50k annual cash retainer plus initial stock option with $300k Black-Scholes value, vesting 1/3 annually over 3 years.
Previously served on boards of GT BioPharma and Verastem.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.